WSFS
RARE icon

Wilmington Savings Fund Society’s Ultragenyx Pharmaceutical RARE Stock Holding History

Wilmington Savings Fund Society’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28
Closed -$1.02K – 1897
2025
Q2 		$1.02K Hold
28
– – ﹤0.01% 1968
2025
Q1 		$1.01K Sell
28
-442
-94% -$18.4K ﹤0.01% 1987
2024
Q4 		$19.8K Sell
470
-1,019
-68% -$50.6K ﹤0.01% 1505
2024
Q3 		$82.7K Buy
+1,489
New +$75.8K ﹤0.01% 1069

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Wilmington Savings Fund Society's RARE Position: Q3 2025 in Review

Wilmington Savings Fund Society sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 28 shares — an estimated $1.02K sold.

Wilmington Savings Fund Society first reported a position in RARE in Q3 2024 and held it in 4 quarters. The position peaked at $82.7K in Q3 2024. 303 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Wilmington Savings Fund Society reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Wilmington Savings Fund Society sold 28 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $1.02K.
  • Wilmington Savings Fund Society first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and held it in 4 quarters.
  • Wilmington Savings Fund Society's Ultragenyx Pharmaceutical position peaked at $82.7K in Q3 2024.
  • 303 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Wilmington Savings Fund Society's 13F filing for Q3 2025, filed 28 Oct 2025.